Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

por Weisel, Katja C., Scheid, Christof, Zago, Manola, Besemer, Britta, Mai, Elias K., Haenel, Mathias, Duerig, Jan, Munder, Markus, Lindemann, Hans-Walter, Seckinger, Anja, Kunz, Christina, Benner, Axel, Hose, Dirk, Jauch, Anna, Salwender, Hans, Goldschmidt, Hartmut
Publicado 2019

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and...

por Salwender, Hans, Bertsch, Uta, Weisel, Katja, Duerig, Jan, Kunz, Christina, Benner, Axel, Blau, Igor W., Raab, Marc Steffen, Hillengass, Jens, Hose, Dirk, Huhn, Stefanie, Hundemer, Michael, Andrulis, Mindaugas, Jauch, Anna, Seidel-Glaetzer, Andrea, Lindemann, Hans-Walter, Hensel, Manfred, Fronhoffs, Stefan, Martens, Uwe, Hansen, Timon, Wattad, Mohammed, Graeven, Ullrich, Munder, Markus, Fenk, Roland, Haenel, Mathias, Scheid, Christof, Goldschmidt, Hartmut
Publicado 2019

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

por Klein, Eva-Maria, Tichy, Diana, Salwender, Hans J., Mai, Elias K., Duerig, Jan, Weisel, Katja C., Benner, Axel, Bertsch, Uta, Akhavanpoor, Mabast, Besemer, Britta, Munder, Markus, Lindemann, Hans-Walter, Hose, Dirk, Seckinger, Anja, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Raab, Marc S., Blau, Igor W., Haenel, Mathias, Scheid, Christof, Goldschmidt, Hartmut
Publicado 2021